At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RNXT RenovoRx Inc
Market Closed 05-10 16:00:00 EDT
1.45
+0.11
+7.81%
盘后1.37
-0.08-5.52%
18:43 EDT
High1.45
Low1.33
Vol24.66K
Open1.42
D1 Closing1.35
Amplitude8.92%
Mkt Cap34.73M
Tradable Cap32.58M
Total Shares23.95M
T/O33.90K
T/O Rate0.11%
Tradable Shares22.47M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Biopharmaceutical Challenger Renovorx: Navigating Uncertainty and Financial Risks in Drug Development
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.